Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Males and Females aged 40-80 with a confirmed diagnosis of sporadic Inclusion Body Myositis~Exclusion Criteria:~* Unable to walk at least 3 meters without assistance from another person~* Use of oral beta agonists, oral corticosteroids, androgens or androgen inhibitors, or intravenous gamma globulin in the last 6 months~* patients with a history or presence of renal impairment and/or liver disease~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BYM338 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).